Benzinga | Mar 23, 2021 07:14AM EDT

SVB Leerink Downgrades Acceleron Pharma to Market Perform, Announces $148 Price Target

SVB Leerink analyst Geoffrey Porges downgrades Acceleron Pharma (NASDAQ:XLRN) from Outperform to Market Perform and announces $148 price target.